G-CAN 2020 Sixth Annual Research Symposium
DRAFT AGENDA for “Virtual Meeting”

October 30, 2020: On-demand pre-recorded video/audio webcasts made available, and questions and answers are posted in the G-CAN chat room.

November 4, 2020: 12:00 noon-16:35 in the afternoon USA Pacific Daylight Time: Live streaming session comprised of pre-recorded video/audio webcasts.

CONFERENCE REGISTRATION: https://bit.ly/2QtyITc

October 30 – November 13: On Demand Webcasts Available Online
G-CAN Chat Room: Questions and responses on individual webcast talks for this year’s virtual meeting will be available online in the chat room for review by all attendees.

60 minutes I. Gout and Hyperuricemia Clinical and Basic Research: The Year in Review
Three 20-minute webcasts (to remain on the G-CAN website indefinitely)
- The Year in Review: Gout Pathophysiology – Nicola Dalbeth, New Zealand
- The Year in Review: Urate Biology and Comorbidities – David Mount, USA
- The Year in Review: Gout Clinical Research – Catherine Hill, Australia

95 minutes II. G-CAN Early Career Investigator Virtual Poster Session
19 five-minute presentations of digitally posted material available October 30 – November 13

1. Yokose, Chio, Boston, US; Hyon Choi, Mentor.
The protective impact of physical activity on the risk of gout in women: prospective cohort study of 82,351 women over 30 years.

2. Jatuworapruk, Kanon, Wellington, New Zealand; William Taylor, Mentor.
Prediction rule for inpatient gout flare in people with comorbid gout: derivation and external validation.

3. Helget, Lindsay, Omaha, US; Ted Mikuls, Mentor.
Cause-specific mortality in patients with gout in the Veteran’s Health Administration: A matched cohort study.

4. Cai, Ken, Auckland, New Zealand; Nicola Dalbeth, Mentor.
The association between gout and cardiovascular disease outcomes: assessment and recalibration of individual-level primary prevention risk prediction equations in approximately 450,000 New Zealanders

5. Vargas-Santos, Ana Beatriz, Boston, US; Tuhina Neogi, Mentor.
Sodium-glucose co-transporter-2 inhibitors and the risk for gout: A comparison among Canagliflozin, Dapagliflozin and Empagliflozin.

Analysis of common gout comorbidities in the UK Biobank Cohort reveals sex-specific effects and genetic differentiation.
   Prospective study of the patterns of joint involvement for sequential gout flares.

8. Flood, Rachel, Tallaght, Ireland; Ronan Mullan, Mentor.
   Metatarsophalangeal joint medial collateral ligament measurement: A novel ultrasound feature of monosodium urate deposition in the joint.

   Initiating gout treatment improves arterial function and reduces intercritical inflammation.

10. Murdoch, Rachel, Auckland, New Zealand; Nicola Dalbeth, Mentor.

11. Roman, Youssef, Richmond, US; Elvin Price, Mentor.
    Genetic perspective on the prevalence of hyperuricemia and gout across major racial groups.

12. Helget, Lindsay, Omaha, US; Ted Mikuls, Mentor.
    Risk factors for mortality among patients with gout in the Veteran’s Health Administration.

    Gout and serum urate levels are associated with lumbar spine monosodium urate deposition and chronic low back pain: A dual-energy CT study.

14. Calabuig, Irene, Alicante, Spain; Mariano Andrés, Mentor.
    Cardiovascular and renal outcomes during the first year of urate-lowering therapy in naïve-gout according to sonographic joint deposits: data from the Lille-Alicante inception cohort.

15. Dombrosky Evan, Richmond, US; Nehal Shah, Mentor.
    Assessing patterns of inpatient gout management with focus on urate-lowering therapy and discharge instructions.

    Role of inflammatory and oxidative stress pathway biomarkers in renal disease in gout.

17. Gavin, Josh, Richmond, US; Nehal Shah, Mentor
    A survey comparing gout management practice patterns of G-CAN members to other rheumatologists.

18. Gromova, Margarita, Moscow, Russia; Vladimir Tsurko, Mentor.
    Complex scintigraphic evaluation of renal and urinary tract dysfunction in patients with arterial hypertension and gout.

19. Kulhawy-Wibe, Stephanie, Calgary, Canada; Paul MacMullan, Mentor.
    Development of a provincial adult inpatient gout management clinical decision-making tool and order set.
100 minutes  III. CPP and BCP Crystal-Associated Arthritis Mini Symposium

10-minute “lightning talks” via webcast; questions on each talk to be submitted by chat room mechanism prior to the live session and answered by authors at the end of the live session

- The Year in Review: CPP Crystal Deposition Disease – Abhishek Abhishek, UK
- Should We Think Differently About the Pathogenesis of CPP Crystal Deposition Disease? – Ann Rosenthal, USA
- OA, Calcium Crystal Deposition and Pain – Tuhina Neogi, Boston
- CPPD Classification Criteria Update – Sara Tedeschi, Boston
- CPPD Advanced Imaging – Georgios Filippou, Italy
- CPPD and Outcome of Knee OA – Pascal Richette, Paris
- BCP Crystal Effects on Inflammatory Cells – Geraldine McCarthy, Dublin
- BCP Crystals, Wnt Signaling and Chondrocyte Differentiation in OA – Jessica Bertrand, Magdeburg
- BCP, Chondrocytes and the Circadian Clock – Raewyn Poulson, Auckland
- Hydrogen Sulfide and Basic Calcium Phosphate Deposition in Arthritis – Nathalie Busso, Lausanne

110 minutes  IV. Advances in Urate and Gout Basic Translational Biology Mini Symposium

10-minute “lightning talks” via webcast; questions on each talk to be submitted by chat room mechanism prior to the live session and answered by authors at the end of the live session

Moderators: Tania Crisan and Alex So

- Urate, XDH, and Vascular Oxidative Stress – Eric Kelley, West Virginia University
- The Effect of SLC2A9 and SLC22A12 Polymorphisms in Urate Homeostasis – Cho Sungkweon, NIH/NCI
- Gene and Environment Interactions in Gout and Urate – Tanya Major, New Zealand
- The Big Gout GWAS – Tony Merriman, USA
- Epigenomics of Gouty Inflammation – Leo Joosten, Nijmegen
- Immunometabolism Targets for Inflammatory Arthritis in Gout – Ru Liu-Bryan, USA
- Circulating and Ex Vivo Cytokine Profiles in Patients with Gout and Hyperuricemia – Tania Crisan-Cluj- Napolca, Romania
- Common Statistical Myths in Basic Translational Biology – Yuqing Zhang, Boston
- Complement Activation by Urate Crystals – Konstantin Neumann, Hanover, Germany
- Molecular Phenotyping of Synovial Fluid Leukocytes from Gout Patients – Richard Reynolds, UAB

November 4 Live Virtual Session
12:00 p.m. – 16:15 (4:15 p.m.) Pacific Daylight Time US

12:00-12:10 Welcome and Introduction to G-CAN, Recognition of Industry Sponsors
G-CAN Co-Directors: Robert Terkeltaub (President) and Hyon Choi (VP and Treasurer)

12:10-12:50 G-CAN Presidential and Gold Medal Awards and Early Career Investigator Lectures
Moderators: Tony Merriman and Nicola Dalbeth

12:50-12:55 G-CAN Gold Medal Investigator Award Lecture
The Genomic Landscape of Hyperuricemia and Gout – Anna Köettgen

12:55-13:00 5-minute question period

12:30-13:30 G-CAN Early Career Investigator Symposium Session
Six Oral Presentations 10 minutes each, with 2 minutes for questions
Moderators: Frédéric Liote and Tuhina Neogi

   Genomic regions jointly associated with eGFR and serum urate: Implications for shared genetic etiology of hyperuricemia and chronic kidney disease.
   Assessing the causal relationships between insulin resistance and hyperuricemia using bi-directional Mendelian randomization.

3. Meyer, Melissa, La Jolla, US; Catherine Hedrick, Mentor.
   Phagocyte Heterogeneity in Resolution of Model Gouty Inflammation.

   Sex differences in expression of renal urate transporters.

5. Leask, Megan, Dunedin, New Zealand; Tony Merriman, Mentor.
   Translating the multi-trait regulatory landscape at SLC2A9.

   Effects of low-fat, Mediterranean, or low-carbohydrate weight loss diets on serum urate and cardiometabolic risk factors over 24 Months; A secondary analysis of a randomized trial.

Jacob M. Wozniak, PhD, University of California San Diego
Brief Introduction by Dr. Tuhina Neogi
Wozniak, Jacob, San Diego, US; Robert Terkeltaub, Mentor.
Sustained xanthine oxidase inhibitor treat to target urate lowering therapy (XOIT2T) coordinately re-wires IL-8 and the blood mononuclear leukocyte mitochondrial and inflammation proteome in gout.

13:45-13:50 5-minute question period

13:50-14:05 G-CAN Presidential Emerging Career Investigator Award Lecture
Target genes, Tissues, and Transcriptional Pathways of Serum Urate Levels – Adrienne Tin

14:05-14:10 5-minute question period

14:10-15:10 Gout Clinical Minisymposium
Lightning Talks of 10 minutes each, with two 10-minute question periods
Moderators: Sarah Stewart and Hyon Choi

14:10-14:20 GoutSMART Feasibility Trial Update – Philip Riches, Scotland
14:20-14:30 Real World Data for Gout Risk Related to SGLT2 inhibitors – Seoyoung Kim, Boston
14:40-14:40 Gout Management in Primary Care Practice – Stephen Juraschek
14:50-14:50 The 2020 ACR Gout Guidelines – John FitzGerald
14:50-15:00 G-CAN Gout Management in CKD Project Final Report – Angelo Gaffo

15:00-15:10 Question Period

15:10-15:20 Urate Deposits in Coronary Arteries – Andrea Klauser,
15:20-15:30 Implications of PERL and CV-Renal Trials in Hyperuricemia and Gout Care – John Forman/Hyon Choi
15:30-15:40 Optimization of Gout Flare Reporting – Nicola Dalbeth, New Zealand
15:40-15:50 Update on G-CAN Common Language Description – Rachel Murdoch, New Zealand
15:50-16:00 Social Media in Crystal Arthritis – Phil Robinson, Australia

16:00-16:05 Question Period

16:05-16:15 Concluding Comments
Robert Terkeltaub and Hyon Choi

16:15 Meeting adjourns
Thank you to G-CAN’s 2019 industry supporters

Roundtable Sponsor and Sponsor of Young Investigator Session

HORIZON PHARMA

AstraZeneca
Sponsors

LG
Affiliate Sponsors

Gout, Hyperuricemia and Crystal-Associated Disease Network, www.g-can.org